SCHEMBL6237845

SCHEMBL6237845

CC(c1cccs1)n1c(=O)oc(=O)c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.43
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 4/20 0.35
HPGD P15428 3/20 0.35
F2 P00734 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 2/20 0.33
SHMT2 P34897 1/20 0.32
HTT P42858 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX5 P09917 1/20 0.32
ALOX15 P16050 1/20 0.32
KLK7 P49862 1/20 0.31
CES2 O00748 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8745086 0.78 POLB (0.47) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL6234144 0.77 MEN1 (0.36) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL1715175 0.77 FAAH (0.38) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL6233910 0.73 POLB (0.37) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL6233039 0.71 POLB (0.36) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL11877823 0.68 MEN1 (0.48) MEN1KMT2AMAPTALDH1A1HPGD
SCHEMBL6234105 0.67 ALDH1A1 (0.35) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL6237841 0.67 HDAC1 (0.47) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL7240590 0.66 POLB (0.54) MEN1KMT2APOLBCYP1A2CYP3A4
SCHEMBL159458 0.66 GPR3 (0.52) KMT2ACYP1A2CYP3A4CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP disclosed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP disclosed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 NQO1 231/4885MEN1 4821/4885KMT2A 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.